Understand the source comparison
Known Adverse Event Data Versus Unknown Human Risk
The in vitro Chonluten paper reported cell-model observations, including inflammatory signaling and cell-behavior findings, not clinical adverse events [2]. That distinction matters because cell activity cannot be used to claim safety in people. More broadly,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The in vitro Chonluten paper reported cell-model observations, including inflammatory signaling and cell-behavior findings, not clinical adverse events [2]. That distinction matters because cell activity cannot be used to claim safety in people.
- More broadly, peptide therapeutics can raise immunogenicity concerns. FDA-affiliated authors have noted that product-related factors, including impurities, can affect immunogenicity risk, and that clinical immunogenicity is influenced by product, patient, and treatment-related factors [14].